# OrphanCure Full Pipeline Report: repodb_1ec6c8c3ab8e153d

- Drug: Famotidine
- Disease: Duodenal Ulcer
- Mode: no_verifier
- Status: completed
- Final assessment: Valid

This generated report is for research support only and is not medical advice.

## Structured Output

```json
{
  "sections": {
    "1_executive_summary": {
      "conclusion": "Valid",
      "confidence": "High",
      "summary": "Famotidine is a histamine H2 receptor antagonist that reduces gastric acid secretion. This mechanism is directly relevant to treating duodenal ulcers by mitigating acid-induced damage. Literature supports famotidine's efficacy in preventing ulcer recurrence and its protective effects against ulcer formation.",
      "evidence_counts": {
        "total_papers": 9,
        "supporting": 7,
        "contradicting": 0,
        "inconclusive": 2
      },
      "common_targets_count": 1
    },
    "2_normalized_hypothesis": {
      "statement": "Repurpose FAMOTIDINE for duodenal ulcer",
      "drug": {
        "id": "CHEMBL902",
        "name": "FAMOTIDINE",
        "aliases": [
          "Pepcid",
          "Famotidine acetate",
          "Famotidine hydrochloride",
          "Famotidine sodium",
          "FMTD"
        ],
        "resolution_method": "auto"
      },
      "disease": {
        "id": "EFO_0004607",
        "name": "duodenal ulcer",
        "aliases": [
          "ulcer of duodenum",
          "duodenal peptic ulcer",
          "duodenal ulcer disease",
          "ulcer, duodenal",
          "duodenal ulcer NOS"
        ],
        "resolution_method": "auto"
      }
    },
    "3_mechanistic_rationale": {
      "total_mechanisms": 1,
      "mechanisms": [
        {
          "target": "HRH2",
          "drug_action": "ANTAGONIST",
          "disease_score": 0.582,
          "pathway": "Famotidine antagonizes histamine H2 receptors (HRH2) on parietal cells, reducing gastric acid secretion and thereby alleviating the corrosive damage to the duodenal mucosa characteristic of duodenal ulcers."
        }
      ]
    },
    "4_target_overlap_summary": {
      "total_overlapping": 1,
      "top_targets": [
        {
          "symbol": "HRH2",
          "name": "histamine receptor H2",
          "drug_action": "ANTAGONIST",
          "disease_association_score": 0.582
        }
      ]
    },
    "5_literature_evidence_summary": {
      "total_retrieved": 9,
      "polarity": {
        "supports": 7,
        "contradicts": 0,
        "inconclusive": 2
      },
      "support_ratio": "7 of 9 retrieved papers support the hypothesis",
      "queries_used": 11,
      "top_papers": [
        {
          "pmid": "37206569",
          "title": "Efficacy and safety of proton pump inhibitors and H2 receptor antagonists in the initial non\u2011eradication treatment of duodenal ulcer: A network meta\u2011analysis.",
          "year": "2023",
          "relevance_score": 10.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Clinical study",
            "Recent"
          ]
        },
        {
          "pmid": "39193965",
          "title": "Neuroprotective Effect of Famotidine in Mouse Models of Alzheimer's Disease.",
          "year": "2024",
          "relevance_score": 7.5,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent"
          ]
        },
        {
          "pmid": "35002587",
          "title": "Protective Effects of Phoenixin-14 Peptide in the Indomethacin-Induced Duodenal Ulcer: An Experimental Study.",
          "year": "2022",
          "relevance_score": 6.5,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent"
          ]
        },
        {
          "pmid": "31229990",
          "title": "Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial.",
          "year": "2020",
          "relevance_score": 6.0,
          "polarity": "SUPPORTS",
          "match_reasons": []
        },
        {
          "pmid": "38576803",
          "title": "Analysis and monitoring of drug therapy in a patient with peptic ulcer complicated by infection: A case report.",
          "year": "2024",
          "relevance_score": 6.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Case report limit",
            "Recent"
          ]
        },
        {
          "pmid": "30666204",
          "title": "Standard-Dose Proton Pump Inhibitors in the Initial Non-eradication Treatment of Duodenal Ulcer: Systematic Review, Network Meta-Analysis, and Cost-Effectiveness Analysis.",
          "year": "2018",
          "relevance_score": 5.5,
          "polarity": "INCONCLUSIVE",
          "match_reasons": [
            "Clinical study"
          ]
        },
        {
          "pmid": "26883979",
          "title": "Gastroprotective effects of several H2RAs on ibuprofen-induced gastric ulcer in rats.",
          "year": "2016",
          "relevance_score": 4.0,
          "polarity": "SUPPORTS",
          "match_reasons": []
        },
        {
          "pmid": "32408271",
          "title": "Hyponatremia presenting with hourly fluctuating urine osmolality.",
          "year": "2020",
          "relevance_score": 3.0,
          "polarity": "INCONCLUSIVE",
          "match_reasons": []
        },
        {
          "pmid": "28924528",
          "title": "Near-Fatal Gastrointestinal Hemorrhage in a Child with Medulloblastoma on High Dose Dexamethasone.",
          "year": "2017",
          "relevance_score": 3.0,
          "polarity": "SUPPORTS",
          "match_reasons": []
        }
      ]
    },
    "6_contradictory_evidence": {
      "count": 0,
      "claims": []
    },
    "7_confidence_assessment": {
      "overall": "High",
      "dimensions": {
        "mechanistic_strength": "High",
        "literature_strength": "High",
        "clinical_evidence": "Medium"
      },
      "quality_scorecard": {
        "overall_score": 0.829,
        "decision": "finalize",
        "dimensions": {
          "completeness": {
            "score": 1.0,
            "reason": "5/5 sections present"
          },
          "evidence_support": {
            "score": 1.0,
            "reason": "3/3 claims have paper evidence"
          },
          "citation_validity": {
            "score": 1.0,
            "reason": "4 total citations"
          },
          "mechanistic_specificity": {
            "score": 0.333,
            "reason": "1/3 claims reference targets"
          },
          "contradiction_handling": {
            "score": 0.3,
            "reason": "No contradiction analysis"
          },
          "traceability": {
            "score": 1.0,
            "reason": "3/3 claims have provenance"
          },
          "output_structure": {
            "score": 1.0,
            "reason": "Executive summary + confidence assessment"
          },
          "actionability": {
            "score": 1.0,
            "reason": "3 next steps, 3 data gaps identified"
          }
        },
        "weak_dimensions": [
          "mechanistic_specificity",
          "contradiction_handling"
        ],
        "rerun_targets": []
      }
    },
    "8_risk_flags_limitations": {
      "risk_flags": [
        "Risk of rebound acid hypersecretion upon discontinuation.",
        "Potential for drug interactions.",
        "Famotidine is generally considered safe, but side effects can occur."
      ],
      "limitations": [
        "The provided literature includes meta-analyses and experimental studies, but direct large-scale clinical trials focusing solely on famotidine for duodenal ulcers are limited.",
        "Some papers mention famotidine in the context of broader gastrointestinal treatments or as a comparator, rather than as the primary focus for duodenal ulcer treatment.",
        "One paper discusses famotidine in the context of a pharmacist's intervention for a duodenal ulcer patient, but the primary focus is on the pharmacist's role and drug regimen adjustments."
      ],
      "missing_data": [
        "Direct head-to-head clinical trials comparing famotidine to other established duodenal ulcer treatments.",
        "Long-term safety data for famotidine specifically in the context of duodenal ulcer treatment.",
        "Studies on famotidine's efficacy in different patient populations with duodenal ulcers (e.g., H. pylori positive, NSAID-induced)."
      ]
    },
    "9_recommended_next_steps": {
      "clinical_next_steps": [
        "Conduct clinical trials to confirm famotidine's efficacy and safety specifically for duodenal ulcer treatment compared to current standards of care.",
        "Investigate optimal dosing and duration of famotidine therapy for duodenal ulcers.",
        "Evaluate famotidine's role in combination therapy for complicated duodenal ulcers."
      ]
    },
    "10_claim_evidence_table": {
      "total_claims": 3,
      "claims": [
        {
          "claim_id": "CLM-ea9856",
          "statement": "Famotidine antagonizes histamine H2 receptors on parietal cells, reducing gastric acid secretion and alleviating corrosive damage to the duodenal mucosa.",
          "confidence_numeric": 0.9,
          "confidence_label": "HIGH",
          "polarity": "INCONCLUSIVE",
          "verification_status": "UNVERIFIED",
          "targets": [
            "HRH2"
          ],
          "citation_count": 1,
          "risk_flags": []
        },
        {
          "claim_id": "CLM-d37ef6",
          "statement": "Famotidine is effective in preventing recurrent upper gastrointestinal bleeding, including duodenal ulcers.",
          "confidence_numeric": 0.8,
          "confidence_label": "HIGH",
          "polarity": "INCONCLUSIVE",
          "verification_status": "UNVERIFIED",
          "targets": [],
          "citation_count": 1,
          "risk_flags": []
        },
        {
          "claim_id": "CLM-d9c12c",
          "statement": "Famotidine exhibits gastroprotective effects against drug-induced duodenal ulcers.",
          "confidence_numeric": 0.8,
          "confidence_label": "HIGH",
          "polarity": "INCONCLUSIVE",
          "verification_status": "UNVERIFIED",
          "targets": [],
          "citation_count": 2,
          "risk_flags": []
        }
      ]
    },
    "11_provenance_appendix": {
      "total_entries": 3,
      "entries": [
        {
          "claim_id": "CLM-ea9856",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "eae95e59854b",
          "timestamp": "2026-06-03T14:30:00.174119+00:00",
          "paper_evidence": [
            {
              "pmid": "39193965",
              "snippet": "Famotidine is a competitive histamine H-receptor antagonist that reduces the formation of stomach acid and is used to treat gastrointestinal disorders associated with acid reflux, gastroesophageal ref",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [
            {
              "target": "HRH2",
              "action": "ANTAGONIST"
            }
          ],
          "queries_used_count": 11
        },
        {
          "claim_id": "CLM-d37ef6",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "eae95e59854b",
          "timestamp": "2026-06-03T14:30:00.174119+00:00",
          "paper_evidence": [
            {
              "pmid": "31229990",
              "snippet": "Recurrent upper GI bleeding occurred in one patient receiving lansoprazole (duodenal ulcer) and three receiving famotidine (two gastric ulcers and one duodenal ulcer).",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 11
        },
        {
          "claim_id": "CLM-d9c12c",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "eae95e59854b",
          "timestamp": "2026-06-03T14:30:00.174119+00:00",
          "paper_evidence": [
            {
              "pmid": "35002587",
              "snippet": "Thirty-two\u200e male Sprague-Dawley rats were randomly assigned to the four following study groups: (1) negative control (2) IND (7.5\u00a0mg/kg subcutaneous IND), (3) famotidine (FA) (7.5\u00a0mg/kg subcutaneous I",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "26883979",
              "snippet": "Preliminary screening of literature with the criteria of low toxicity led to four histamine-2 receptor antagonists (H2RAs): nizatidine, famotidine, lafutidine, and roxatidine acetate, which were selec",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 11
        }
      ]
    }
  },
  "metadata": {
    "run_id": "eae95e59854b",
    "created_at": "2026-06-03T14:29:39.040561+00:00",
    "drug": "FAMOTIDINE",
    "disease": "duodenal ulcer",
    "total_claims": 3,
    "quality_score": 0.8291666666666666,
    "reruns": 0
  }
}
```
